<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/464D389D-37E8-4F35-8E73-3DE6F1D2DA17"><gtr:id>464D389D-37E8-4F35-8E73-3DE6F1D2DA17</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Harvey</gtr:otherNames><gtr:surname>Adams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D1D6A61-91DB-4223-BB27-2D6366831BFA"><gtr:id>6D1D6A61-91DB-4223-BB27-2D6366831BFA</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Taylor-Robinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1DE4B870-CDF2-410E-AB0D-BB95C0AC0388"><gtr:id>1DE4B870-CDF2-410E-AB0D-BB95C0AC0388</gtr:id><gtr:firstName>Gideon</gtr:firstName><gtr:surname>Hirschfield</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AA7333DC-6BA3-47A6-8236-DDC2BDE299B9"><gtr:id>AA7333DC-6BA3-47A6-8236-DDC2BDE299B9</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Shirley</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77B2189C-07F0-4EBA-A2A5-A58AD53ECF78"><gtr:id>77B2189C-07F0-4EBA-A2A5-A58AD53ECF78</gtr:id><gtr:firstName>Deborah</gtr:firstName><gtr:surname>Stocken</gtr:surname><gtr:orcidId>0000-0001-8031-1738</gtr:orcidId><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F8BD667B-B750-47A0-8980-3E53A9FC3472"><gtr:id>F8BD667B-B750-47A0-8980-3E53A9FC3472</gtr:id><gtr:firstName>Elaine</gtr:firstName><gtr:surname>Holmes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/488FC86F-BFA0-4AEE-ADAA-3F0A6B4D18BE"><gtr:id>488FC86F-BFA0-4AEE-ADAA-3F0A6B4D18BE</gtr:id><gtr:firstName>Luke</gtr:firstName><gtr:surname>Vale</gtr:surname><gtr:orcidId>0000-0001-8574-8429</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AE7EA01F-0FBC-454A-9BBC-762E455AC90B"><gtr:id>AE7EA01F-0FBC-454A-9BBC-762E455AC90B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Emrys</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1363D81C-25C3-4E07-856F-519FE2F07399"><gtr:id>1363D81C-25C3-4E07-856F-519FE2F07399</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Kirby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/914F62BF-EE62-41B2-A1CC-B45DB8B0161A"><gtr:id>914F62BF-EE62-41B2-A1CC-B45DB8B0161A</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Rushton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E5534416-95D1-4ECC-ADA0-80AAE4BA9B87"><gtr:id>E5534416-95D1-4ECC-ADA0-80AAE4BA9B87</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Afford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/09FD25F3-7FC1-4A92-87F4-AC0C027888B9"><gtr:id>09FD25F3-7FC1-4A92-87F4-AC0C027888B9</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:surname>Marchesi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AE4875FD-7BA6-4608-BFDE-E30E1365BB4F"><gtr:id>AE4875FD-7BA6-4608-BFDE-E30E1365BB4F</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Sandford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0A0DE806-2BAC-4CEC-BD38-781D63A5F50B"><gtr:id>0A0DE806-2BAC-4CEC-BD38-781D63A5F50B</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Oakley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL001489%2F1"><gtr:id>39FE6A03-3CF4-4226-8016-BB9CF55F572A</gtr:id><gtr:title>Stratified Medicine in Primary Biliary Cirrhosis (PBC): Understanding Disease Mechanisms and Targeting Therapies (UK-PBC)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L001489/1</gtr:grantReference><gtr:abstractText>Primary Biliary Cirrhosis (PBC) is a chronic liver disease affecting 20,000 patients in the UK. The aim of our project is to transform our capacity to treat it. The problem is that whereas many PBC patients respond well to treatment with a drug called ursodeoxycholic acid (&amp;quot;urso&amp;quot;) around 30% do not. We now know that when people don't respond to urso they run a real risk of their liver disease getting worse over time, leading ultimately to cirrhosis with all its complications and for which the only treatment is liver transplantation. The goal of the UK-PBC project, which is supported by academic centres, doctors, patient groups and industry throughout the UK, is to understand why it is that some people don't respond to urso, to find better ways of predicting who will and won't respond, and to identify the best way to treat people who don't respond (a number of drugs have been suggested as sensible treatments for people who don't respond to urso but at present we don't know how and in whom to use them). We are working with patient groups to recruit over half of all urso non-responding PBC patients in Britain (we have already recruited a third) making this a truly unique study. Our preparatory studies have already shed light on why people are at risk of PBC, and have shown that PBC is less likely to respond to treatment in young patients and in men. We now need to know why and to know what we can do about it.

The UK-PBC study will be in 3 sections. In the 1st section we will work with the PBC Foundation to recruit patients and to organise to collect important clinical information, together with a blood sample. The clinical information will allow us to identify whether someone has responded to urso or not (as well as how bad their symptoms are). The blood samples will allow us to understand key aspects of people's make up, including their genes and the way their immune system works, and the differences in make up between people who do and don't respond to urso. In addition to the main group of patients we will invite a smaller group of patients who are at very high risk of not responding to urso (those in whom PBC was diagnosed below the age of 50), or who have already not responded, to take part in a more detailed study in which we explore the actual damage to their liver in the 2nd section of the study.

In the 2nd section of our study we will explore what is different about PBC in people who do and don't respond to urso. This will allow us to identity the processes that cause non-response and to identify the best possible treatments for people who don't respond. It is thought that PBC is caused by the immune system mis-identifying the cells that line the bile duct and trying to reject them. This leads to damage to the bile ducts which impairs bile flow. Bile, which is toxic, then builds up in the liver causing more damage to the bile ducts and thus further bile duct injury. Injury eventually leads to scarring, and ultimately cirrhosis. In the second study section we will explore whether people who don't respond to urso have a more aggressive immune response than responders, have more toxic bile, have bile duct cells that react differently to injury (coping less well) or are more susceptible to liver scarring. Critically, all of these potential causes match up to existing potential treatments, or areas where new treatments can be developed rapidly. 

In the 3rd section we will work with patient groups and industry partners to develop a national approach to studying new drugs in PBC to make it easier and more cost-effective to explore new drugs; a step which will encourage companies to want to develop new treatments which will ultimately benefit patients. We also begin to develop a national approach to treatment of PBC so that all patients benefit from the best possible treatments.

Our goal is nothing less than a transformation in our understanding of how to treat this significant disease</gtr:abstractText><gtr:technicalSummary>Primary biliary cirrhosis (PBC) is the commonest autoimmune liver disease and a significant cause of morbidity and mortality. Ursodeoxycholic acid (UDCA), the only licensed therapy, slows progression to cirrhosis, but response is inadequate or absent in around 30% of patients, with non-responders facing a 5-fold increased risk of death or need for liver transplant. There is substantial industry interest in novel approaches to treating UDCA non-responders, but little information is available regarding mechanisms underpinning failure to respond to UDCA precluding informed decision making about which agents to take to clinical trial as second-line therapies. We will further develop the 5000 person UK-PBC patient cohort, the largest and best characterised in the world, by targetting recruitment of existing UDCA non-responding patients, and those at high risk of future non-response (for reasons of age), and will utilise it to explore the mechanisms of UDCA non-response. We will work with our industrial and patient-group partners to develop and deliver innovative clinical trials of stratified therapy, and will explore structured approaches to the future delivery of care nationally in PBC. The multi-disciplinary UK-PBC research consortium (www.UK-PBC.com) is fully established and has published landmark clinical and mechanistic studies. A multi-strand approach will be used in which patients will be recruited, pheno-, sero- and genotyped and stratified for UDCA response. A nested cohort of highly informative high-risk/non-responding patients will undergo more detailed cell- &amp;amp; tissue-based study with correlation of biological and clinical outcomes. Mechanistic themes addressing the core pathological processes in PBC will be able to access informative patients to undertake studies aimed at addressing the mechanisms and markers of non-response and identifying optimal therapeutic approaches. Our goal is to move to targeted clinical intervention by the end of the funding period.</gtr:technicalSummary><gtr:potentialImpactText>The proposed project is predicated on delivery of impact to both patients and industry. The potential beneficiaries of this project include patients with PBC, the NHS, and Industrial partners. 

PBC PATIENTS: It is now clear (and the outline data from UK-PBC confirm this) that there is significant unmet need in PBC, with an important sub-group of patients failing to respond to current licensed therapy. The goal of the UK-PBC project is to understand the biology of non-response and to improve therapy by targetting, evaluating, and, where needed, developing second-line therapies. UK-PBC will also provide a platform for future studies of therapy for the important and life altering symptoms of PBC, although this is not the primary focus of the current application. Benefit to patients will therefore come through improved therapy for, typically young, high-risk patients. Successful applications of second line therapy will both lengthen survival and, we would anticipate, improve the quality of life of patients. The patient groups are strong advocates for UK-PBC and have played a critical role in developing the project to its current form. They will be the major beneficiaries of project impact.

THE NHS: PBC represents an important cause of end-stage liver disease with up to 10% of liver transplants in the UK still being for end-stage PBC. The development and application of effective second-line therapy would benefit the NHS through reducing the need for liver transplantation in end-stage disease (an extremely costly treatment) and by reducing the costs associated with its clinical manifestations (variceal bleeding, management in intensive care units etc). Clearly, should effective second-line therapy reduce the need for transplant in PBC there will be additional beneficiaries, namely patients with other forms of chronic liver disease for whom transplant is necessary and whose chances of receiving an organ will be increased if the need for organ use in PBC is reduced. Depending on the nature of effective second-line therapy there is also significant potential for a fundamental change in delivery of care in PBC, with a move away from specialist clinics for the majority of patients, who are in fact low risk, to targeted therapy delivered in a primary care setting. This aspect is addressed in more detail in the pathways to impact document. UK-PBC is fully engaged with exploring pathways to enhance care delivery in PBC as well as undertaking the mechanistic studies outlined in this proposal. 

INDUSTRY: There is considerable industrial interest in PBC. There are, however, key questions we need to answer regarding identification of the most appropriate second-line therapies, how to identify potential recipients, and how to deliver effective trials. There is also a need for more robust biomarkers to identify high risk disease allowing a change in treatment paradigm to more effective therapy given earlier in the disease course. The UK-PBC platform will provide a unique opportunity to explore the mechanistic basis of failure to respond to primary therapy, allowing informed decision making regarding second-line agents. The infrastructure and patient cohorts of UK-PBC will also provide a unique platform to undertake focussed second-line therapy trials in PBC. The potential offered here is reflected in the interest shown by industry in the UK-PBC initiative, with companies investing in the programme as well as offering support. In addition to pharmaceutical company interest the opportunities around enhanced sero-diagnosis and biomarker development to enable better characterisation of risk in this disease have proved to be of significant interest to biomarker and serology companies who are also partners in the project. 

The UK-PBC consortium members have a strong track record of delivering impact in PBC and the infrastructure provided by a stratified medicine programme would transform our capacity to benefit patients.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4842137</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pfizer biomarkers funding</gtr:description><gtr:id>272A8F50-0220-4A55-802C-F1658FC5973B</gtr:id><gtr:impact>No outcomes so far.</gtr:impact><gtr:outcomeId>56dd60df350743.56339352-1</gtr:outcomeId><gtr:partnerContribution>Pfizer have provided funding to allow the assessment to be carried out.</gtr:partnerContribution><gtr:piContribution>The research team is performing a cohort based assessment of risk biomarkers in PBC and providing Pfizer with data and reports.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Precision Medicine Collaboration Nation event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>558AB7DF-0CBC-4A82-91E7-90DD1A57A047</gtr:id><gtr:impact>The strength of UK-PBC partnerships (academic, industry, patient and funders) featured as an illustration of how vital partnerships are in research. UK-PBC achievements relating to this featured in the opening section at the Precision Medicine Collaboration Nation event 9th December 2015</gtr:impact><gtr:outcomeId>56cc739fc93393.47350939</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.uk-pbc.com/newsevents/uk-pbcfeaturesatmajornationalevent.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science on a plate - Local School Engagement</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E53B83D5-2A50-4298-B6FB-AC3343E84DE5</gtr:id><gtr:impact>The workshops gave students a better understanding of liver disease physiology

unknown</gtr:impact><gtr:outcomeId>5461f5bf362827.40293840</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://research.ncl.ac.uk/fibrosislab/newsevents/publicengagement/scienceonaplatesoap/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regional PBC updates</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C714DA67-8ACD-41A8-AC4B-1E2E5BAAA04B</gtr:id><gtr:impact>Six regional &amp;quot;teach-ins&amp;quot; and case discussions for local GI consultants around the UK to educate on current PBC management.</gtr:impact><gtr:outcomeId>56d84722a52c74.04085774</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Releases Presented at 50th European Association for the Study of the Liver (EASL) by Industry Partners Intercept</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2AEE5FBA-4AEB-400E-8176-0F57B82A1FCB</gtr:id><gtr:impact>Industry partner Intercept presented new data to inform EASL attendees and journalists of UK-PBC related research.</gtr:impact><gtr:outcomeId>56caff00a53b62.73766199</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://globenewswire.com/news-release/2015/04/13/723692/10128520/en/Intercept-Announces-New-Data-in-PBC-and-NASH-to-be-Presented-at-EASL-2015.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cholestasis Past Present and Future</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CA4238CA-6288-47A7-A98C-F97808AC745F</gtr:id><gtr:impact>Launched in 2014, a science meeting bringing together the field leaders in cholestasis to discuss cutting edge science. Hosted by UK-PBC this has played an important role in building the &amp;quot;brand&amp;quot; of UK-PBC. Run again in 2015 and will henceforth be bi-annual</gtr:impact><gtr:outcomeId>56d845d49e3b09.99580763</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.profbriefings.co.uk/ppfcholestasis2015/</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Table at Genetics Matters Event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2F722B34-2BB6-4FE5-906F-6E3E3D39D29B</gtr:id><gtr:impact>Table at the Genetics Matters event in Newcastle Upon Tyne with a selection of print outs showing:

- differences between healthy and ill liver and bile duct
- some of the concurrent symptoms that individuals get (e.g. xanthoma)
- some visual stats about epidemiology and genetic overlap with other conditions
- manhattan plots from most recent GWAS</gtr:impact><gtr:outcomeId>56cc72a48ef513.72685828</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://blogs.ncl.ac.uk/igmengagement/27th-february-2016-genetics-matters/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Teaching Sessions on Stratified care in PBC</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>20422D88-BE0D-4710-8AD3-A307CEBA4928</gtr:id><gtr:impact>National teaching sessions carried out in conjunction with Falk and Pharma. Additional teaching sessions at DDF and AASLD.</gtr:impact><gtr:outcomeId>56cb03054b4780.44916484</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Industrial strength research Interview with MRC</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F99A8A22-158B-44DB-BCCD-EC9F13F4768B</gtr:id><gtr:impact>In an interview with the MRC, Professor Jones explained why it is vitally important for academic and industry researchers to collaborate, and how UK-PBC is at the forefront of this.</gtr:impact><gtr:outcomeId>56cc740db6e713.09460906</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.mrc.ac.uk/news/browse/industrial-strength-research/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK-PBC Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>48FEE5A4-0429-4411-A766-BEA604B4FEF5</gtr:id><gtr:impact>An educational session at DDF in June 2015 emphasising the importance of PBC and other autoimmune liver diseases and the clinical challenges. Aimed at clinical trainees.</gtr:impact><gtr:outcomeId>56d840348eccd8.25296824</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ddf2015.org.uk/docs/default-source/default-document-library/liver-at-ddf201595759eb19f8d60cab65fff0000695d64.pdf?sfvrsn=0</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Treatment Landscape of PBC Video</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>84E632B8-0446-4B8A-A547-5082FDF95815</gtr:id><gtr:impact>Gideon Hirschfield, UK-PBC member talks to Medpage about the Treatment Landscape of PBC</gtr:impact><gtr:outcomeId>56cb03e271c6b0.69447287</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.medpagetoday.com/PBCandNASHRapidResponseVideo/Gastroenterology/GeneralHepatology-Videos/1103</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Leading Edge - School workshops</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2AE6ABD8-4C2C-4EC8-97A8-9CDB2E50693A</gtr:id><gtr:impact>The day gave students an increased understanding of liver disease and information about a career in academia

Students visited the Fibrosis lab at Newcastle University</gtr:impact><gtr:outcomeId>5461f6a33083a4.24422046</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://research.ncl.ac.uk/fibrosislab/newsevents/publicengagement/leadingedge/</gtr:url><gtr:year>2010,2011,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New model for consultation around clinical guidelines</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FA10C34B-1E69-404A-BE7C-AC8B2CA6054C</gtr:id><gtr:impact>We have worked with patient organisations to develop a new model for involving patients in new or updated clinical guidelines</gtr:impact><gtr:outcomeId>58c817737bad89.64597998</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Group Meetings</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D4C12156-6B39-41F5-8E47-616BFE2F004E</gtr:id><gtr:impact>PBC patient research update meetings. These are held around the region 6 times per year to explain our research, the rationale behind it, the key findings and what this means and may mean for the future improvements in treatment

In addition to their intrinsic worth these meetings hold substantial benefits in terms of recruitment rates for our studies.</gtr:impact><gtr:outcomeId>9487DDD5573</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2009,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>27820</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Data Input support</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Lumena Pharmaceuticals</gtr:fundingOrg><gtr:id>D7E1E069-2107-49D2-8916-7EFE255DEDF0</gtr:id><gtr:outcomeId>5461e40a529435.29449228</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HPRU: Toxicology of Chronic Disease</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>62C59D3A-B9B0-4205-839F-5493DA57610F</gtr:id><gtr:outcomeId>5461e8c7a22c45.87800064</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>262000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Training Fellowship</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BCB9A466-B385-479C-8419-CB48A744F4CD</gtr:id><gtr:outcomeId>5461edcf9c6434.80298025</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1052135</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Research Fellowship (H Cordell)</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>102858/Z/13/Z</gtr:fundingRef><gtr:id>6C8F7BE8-B662-42D3-96EC-FF2D54531A7D</gtr:id><gtr:outcomeId>5461ea85b75ad9.49962003</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Sheila Sherlock Fellowship</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>European Association for the Study of the Liver (EASL)</gtr:fundingOrg><gtr:id>393165DA-3007-490B-8E0E-7BE95F46C365</gtr:id><gtr:outcomeId>5461fdd39c4d81.58122638</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22169</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OCA on cognitive Symptoms</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Intercept Pharmaceuticals</gtr:fundingOrg><gtr:id>52071CB1-8DD2-4F59-9AEF-FBC9D10598EF</gtr:id><gtr:outcomeId>5461ee696c0940.99761363</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>560000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TRC Doctoral and Postdoctoral Fellowships (G Mells and J Dyson)</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>EFD5C9A0-B0EA-46FD-9CF0-9B820352FC45</gtr:id><gtr:outcomeId>5461e9a981fdc9.31434445</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cohort Development</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Intercept Pharmaceuticals</gtr:fundingOrg><gtr:id>140F5C5A-A0A9-4978-8A7A-0BA14D177ABE</gtr:id><gtr:outcomeId>5461e3ad24d793.14181982</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Meeting Organisation</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Intercept Pharmaceuticals</gtr:fundingOrg><gtr:id>975C0639-6862-4D67-B1D7-B1C5E775586E</gtr:id><gtr:outcomeId>5461e4762ea036.87917601</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Substantial contribution to the data set and process around FDA and EMA approval for, and NICE assessment (positive) of OCALIVA, a new drug for PBC</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>69595FAD-BF0F-4711-AB32-1D40CED095F8</gtr:id><gtr:outcomeId>58c81873a30ee9.76514667</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus</gtr:description><gtr:id>13170AC8-6721-4D6D-9E11-4745FBE4F15D</gtr:id><gtr:impact>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus</gtr:impact><gtr:outcomeId>58c928df5732e0.95699776</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>GSK2330672</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
Sponsor: CymaBay</gtr:description><gtr:id>6B82E365-A342-44F3-B76E-BCA3BDE3DF24</gtr:id><gtr:impact>Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
Sponsor: CymaBay</gtr:impact><gtr:outcomeId>58c928857da3f9.82630971</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The new UK-PBC Database had been developed by Dr Tony Bennett from Illuminaries Ltd&amp;reg;. 
This database allows research staff in collaborating centres to log into it from any NHS computer to view information about participants recruited from their own centres and to complete Case Record Forms (CRFs) online and upload the results of medical investigations directly into the database.
The database went live towards the end of 2015 and research teams in most collaborating centres have started to use it.</gtr:description><gtr:id>BBA75F21-277C-4FC1-B747-92E9AC9230A8</gtr:id><gtr:impact>Research teams have found the database easy to use - and better than the previous, paper-based system.</gtr:impact><gtr:outcomeId>56cb04d2add6b2.56147205</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>UK-PBC Database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.uk-pbc.com/newsevents/UKPBC%20Newsletter.pdf</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>The app estimates the risk (expressed in percentage) that a PBC patient established on treatment with Ursodeoxycholic acid (UDCA) will develop liver failure requiring liver transplantation within 5, 10 or 15 years from diagnosis.

The score may be used to identify high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who could potentially be followed-up in primary care.</gtr:description><gtr:id>F223DB09-698B-449A-AADB-B2D21377CAD9</gtr:id><gtr:impact>Too early for impact to have been realised.</gtr:impact><gtr:outcomeId>56cb0206e76fd7.38046150</gtr:outcomeId><gtr:title>UK-PBC Risk Score iPhone App</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:url>http://www.uk-pbc.com/newsevents/uk-pbcriskscoreiphoneappnowavailable.html</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>The calculator uses information from the UK-PBC Research Cohort to estimate the risk (expressed in percentage) that a PBC patient established on treatment with Ursodeoxycholic acid (UDCA) will develop liver failure requiring liver transplantation within 5, 10 or 15 years from diagnosis.

The calculator is in the format of an Excel spreadsheet.</gtr:description><gtr:id>678AECC3-E027-4731-905C-CE6FD9B01CFF</gtr:id><gtr:impact>Provision of UK-PBC Risk Calculator for patients, practitioners and public to download for information.</gtr:impact><gtr:outcomeId>56cc760820baf4.50170559</gtr:outcomeId><gtr:title>UK-PBC Risk Calculator</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://www.uk-pbc.com/resources/tools/riskcalculator/</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FB0B7C2A-DB93-4EE5-9E78-746AF99D5929</gtr:id><gtr:title>Editorial: scoring systems in primary biliary cholangitis - time to make a move.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>58c80f243e4de3.03232348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20EB6131-4FE2-43CE-AFB7-872813016F56</gtr:id><gtr:title>Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00bf7e61704af89a644d08942a3a5ecb"><gtr:id>00bf7e61704af89a644d08942a3a5ecb</gtr:id><gtr:otherNames>Hegade VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58c813849c28d9.08006313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47BF5B13-63A1-4D68-900F-D2831AC9EE6E</gtr:id><gtr:title>New model to identify UDCA-treated primary biliary cirrhosis patients in need of additional therapy. Results of an international follow-up study of 4119 patients</gtr:title><gtr:parentPublicationTitle>Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d00e4a5d860dab63cd90843bfaa5ff6"><gtr:id>3d00e4a5d860dab63cd90843bfaa5ff6</gtr:id><gtr:otherNames>Lammers WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461dccaa155e0.78889006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45DD4692-8312-478A-A3D3-4AB11F3CA6EE</gtr:id><gtr:title>Liver disease in the UK</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/401c95cec7adacde911bf2c990400f54"><gtr:id>401c95cec7adacde911bf2c990400f54</gtr:id><gtr:otherNames>Hirschfield G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56cc825a2ec827.50653106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AE1F794-F823-4E3E-BB5F-314340839EF9</gtr:id><gtr:title>Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15118_28_23471852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A682F250-1A4E-4DE2-9BDA-3899BBF390E2</gtr:id><gtr:title>Promoting self-management and adherence with strength and balance training for older people with long-term conditions: a mixed-methods study.</gtr:title><gtr:parentPublicationTitle>Journal of evaluation in clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04a0a8da3813515e96fa3681efaa0ed4"><gtr:id>04a0a8da3813515e96fa3681efaa0ed4</gtr:id><gtr:otherNames>Robinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1356-1294</gtr:issn><gtr:outcomeId>5461f2bd89c263.60206634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96486016-58A4-41E5-8FC4-B904643D80E0</gtr:id><gtr:title>Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb0cc0109e179d19fdeb7c8dc774a9c6"><gtr:id>bb0cc0109e179d19fdeb7c8dc774a9c6</gtr:id><gtr:otherNames>Hirschfield GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56cc7d56513e38.98984912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBDED32A-9A0C-4C8C-8807-8A463BFC88E8</gtr:id><gtr:title>Early Molecular Stratification of High-risk Primary Biliary Cholangitis.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb1d19b3a013e11e74b4ddd27ec8a2b1"><gtr:id>fb1d19b3a013e11e74b4ddd27ec8a2b1</gtr:id><gtr:otherNames>Hardie C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>58c8127fd97630.67322161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1389D92-ACAE-4CD8-9FA4-8CECD581785E</gtr:id><gtr:title>The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00bf7e61704af89a644d08942a3a5ecb"><gtr:id>00bf7e61704af89a644d08942a3a5ecb</gtr:id><gtr:otherNames>Hegade VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>58c1480e26d918.61193681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EA128BC-FE6A-4132-B6CA-37C871199CD5</gtr:id><gtr:title>Age at Presentation and Gender are Predictors of Increased Mortality Over Long-Term Follow-Up in Primary Biliary Cirrhosis (PBC)</gtr:title><gtr:parentPublicationTitle>Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df2edbaa1215d66fb561f6798d413656"><gtr:id>df2edbaa1215d66fb561f6798d413656</gtr:id><gtr:otherNames>Dyson JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461e18d7aa524.19649477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F7D9C12-CD8E-488A-B9A3-99604AF1E68E</gtr:id><gtr:title>Unmet clinical need in autoimmune liver diseases.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df2edbaa1215d66fb561f6798d413656"><gtr:id>df2edbaa1215d66fb561f6798d413656</gtr:id><gtr:otherNames>Dyson JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5461f2bd12dfa8.34043770</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBB7C493-AA23-484D-94E8-0C12CB0B4F17</gtr:id><gtr:title>BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMC gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00bf7e61704af89a644d08942a3a5ecb"><gtr:id>00bf7e61704af89a644d08942a3a5ecb</gtr:id><gtr:otherNames>Hegade VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-230X</gtr:issn><gtr:outcomeId>58c14a71a92cd9.92403420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EE65570-5370-4715-90DD-05049B2E4A55</gtr:id><gtr:title>The Immunogenetics of Autoimmune Cholestasis.</gtr:title><gtr:parentPublicationTitle>Clinics in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15e68c617b011357137d3bb9f8bef859"><gtr:id>15e68c617b011357137d3bb9f8bef859</gtr:id><gtr:otherNames>Trivedi PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1089-3261</gtr:issn><gtr:outcomeId>585d53927b6fe2.18055658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D00CA18-3074-40E8-8A03-C225EF172507</gtr:id><gtr:title>Obeticholic acid for the treatment of primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Expert review of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15e68c617b011357137d3bb9f8bef859"><gtr:id>15e68c617b011357137d3bb9f8bef859</gtr:id><gtr:otherNames>Trivedi PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1751-2433</gtr:issn><gtr:outcomeId>58c149995ae733.63610570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C317C527-E61F-4549-9709-109464C016A3</gtr:id><gtr:title>Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d4b10bef9940042a07f07fab866601"><gtr:id>11d4b10bef9940042a07f07fab866601</gtr:id><gtr:otherNames>Carbone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_15118_28_23246637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2B43A88-08CA-4579-99C5-658085DD13CE</gtr:id><gtr:title>Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.</gtr:title><gtr:parentPublicationTitle>Digestive diseases and sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00bf7e61704af89a644d08942a3a5ecb"><gtr:id>00bf7e61704af89a644d08942a3a5ecb</gtr:id><gtr:otherNames>Hegade VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0163-2116</gtr:issn><gtr:outcomeId>58c14752298bc2.26136722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55860E64-0412-40CA-89C3-AEB986DD6998</gtr:id><gtr:title>The immunogenetics of primary biliary cirrhosis: A comprehensive review.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>58c14bcb4bad20.69216964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43F4E0EE-DE04-4010-B935-A3583AD7FF59</gtr:id><gtr:title>Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5463270c424af5.97834638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E7E1578-4973-4FFF-86CD-7BF3DCAC0310</gtr:id><gtr:title>Orthostatic intolerance is common in chronic disease--a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afa82016345f415704bcfe5850a2f651"><gtr:id>afa82016345f415704bcfe5850a2f651</gtr:id><gtr:otherNames>Frith J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn><gtr:outcomeId>5461f2bdad6283.72268662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F9A3274-21DD-402D-853A-3631D13F5585</gtr:id><gtr:title>Vascular cell adhesion molecule 1 expression by biliary epithelium promotes persistence of inflammation by inhibiting effector T-cell apoptosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c09ab949db1e04a2c7b6f1ec3230524"><gtr:id>2c09ab949db1e04a2c7b6f1ec3230524</gtr:id><gtr:otherNames>Afford SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5461fe5fab8575.66899945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F4B685B-1398-4957-805C-D236F39C00A7</gtr:id><gtr:title>The new epidemiology of primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Seminars in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bae66f1ffefc35438ffca7121f8ed2f8"><gtr:id>bae66f1ffefc35438ffca7121f8ed2f8</gtr:id><gtr:otherNames>Griffiths L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0272-8087</gtr:issn><gtr:outcomeId>5461f2bcda6995.51762705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C535E05-BEBC-4490-841B-0C5473368F44</gtr:id><gtr:title>The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d4b10bef9940042a07f07fab866601"><gtr:id>11d4b10bef9940042a07f07fab866601</gtr:id><gtr:otherNames>Carbone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15118_28_23628322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0D638EA-1D6B-4F67-AA04-476A8E441666</gtr:id><gtr:title>Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d00e4a5d860dab63cd90843bfaa5ff6"><gtr:id>3d00e4a5d860dab63cd90843bfaa5ff6</gtr:id><gtr:otherNames>Lammers WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>5463270c6f8507.46865473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1E481B9-B85A-4ADD-ADF7-01840858D04E</gtr:id><gtr:title>Stratified medicine and primary biliary cholangitis.</gtr:title><gtr:parentPublicationTitle>The lancet. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a9e72b1c9cbf8.85517728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF2A6769-DCA5-4EB6-96A9-481B07A5756F</gtr:id><gtr:title>Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.</gtr:title><gtr:parentPublicationTitle>Clinics in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8b3a98515dda0ce4f419ee1dee150db"><gtr:id>a8b3a98515dda0ce4f419ee1dee150db</gtr:id><gtr:otherNames>Jopson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1089-3261</gtr:issn><gtr:outcomeId>58c14839a5e729.97036964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>227F2EAC-1180-473F-833F-542375C3BD74</gtr:id><gtr:title>The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bef041439a8509eeada0bb3b6f6319a1"><gtr:id>bef041439a8509eeada0bb3b6f6319a1</gtr:id><gtr:otherNames>Pells G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15118_28_23466308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F98986F-94DE-4CB9-BB72-AA23DF781144</gtr:id><gtr:title>Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f39b0f644ff69e364b44fc152ae1d535"><gtr:id>f39b0f644ff69e364b44fc152ae1d535</gtr:id><gtr:otherNames>Lleo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5461fe5f84a989.84129264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53C2979F-B130-4548-9CE3-C2C272B38714</gtr:id><gtr:title>Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15e68c617b011357137d3bb9f8bef859"><gtr:id>15e68c617b011357137d3bb9f8bef859</gtr:id><gtr:otherNames>Trivedi PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56cc7d060ef0d9.87709229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1141A48-9E80-4DCF-BC20-29F1E375D474</gtr:id><gtr:title>Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn><gtr:outcomeId>5a9e750f0bea62.86934181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA5E12C1-9415-4B31-82D9-67AF5D0BAC9F</gtr:id><gtr:title>Changing Nomenclature for PBC from &amp;quot;Primary Biliary Cirrhosis&amp;quot; to &amp;quot;Primary Biliary Cholangitis&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1076da40c1cbba821462d2bbc931bd83"><gtr:id>1076da40c1cbba821462d2bbc931bd83</gtr:id><gtr:otherNames>Tanaka A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0944-1174</gtr:issn><gtr:outcomeId>58c14b2b9c09b0.17050271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB2BE8D9-6147-4DF2-92B7-93F664043B47</gtr:id><gtr:title>A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd470b2edf9dbceead7f4c1dc40949c7"><gtr:id>bd470b2edf9dbceead7f4c1dc40949c7</gtr:id><gtr:otherNames>Patanwala I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56caf1f47aa599.36066992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7C6E25B-882B-4DFF-9BED-5B83EB34E547</gtr:id><gtr:title>A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e39a8cff411e5b920f58386d2b83870"><gtr:id>2e39a8cff411e5b920f58386d2b83870</gtr:id><gtr:otherNames>Nevens F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>58c1479ae052e0.09406279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B71125A-1481-4491-9F1A-A66D5D11A92F</gtr:id><gtr:title>Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad20b0affb1ad067d0c89b85c200083e"><gtr:id>ad20b0affb1ad067d0c89b85c200083e</gtr:id><gtr:otherNames>Grover VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>58c14711e65170.70771063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39DD66B3-FA15-4754-80FA-F725609792FC</gtr:id><gtr:title>Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b0127cc9b7596900037c9a7b5a0d12"><gtr:id>b2b0127cc9b7596900037c9a7b5a0d12</gtr:id><gtr:otherNames>Cheung AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>58c1489b9b14f0.53120642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A527EA9-D481-4D4C-9EE9-156B4CEEDA52</gtr:id><gtr:title>What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e394347bae35d33f28c934bb3138fbcc"><gtr:id>e394347bae35d33f28c934bb3138fbcc</gtr:id><gtr:otherNames>Wong LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>5a9e72b228f586.63225662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DB8334C-79F2-4CF5-A2FC-B80ED6137BBA</gtr:id><gtr:title>Novel strategies and therapeutic options for the management of primary biliary cholangitis.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/489373965ab04071bf9b5ed689f0362c"><gtr:id>489373965ab04071bf9b5ed689f0362c</gtr:id><gtr:otherNames>Khanna A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1756-283X</gtr:issn><gtr:outcomeId>5a9e72b1f21068.50644499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96680B83-91BF-4B72-A60A-E4B635344B98</gtr:id><gtr:title>Pathogenesis of primary biliary cirrhosis and its fatigue.</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bae66f1ffefc35438ffca7121f8ed2f8"><gtr:id>bae66f1ffefc35438ffca7121f8ed2f8</gtr:id><gtr:otherNames>Griffiths L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>5461f2bd638253.59142768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72BCE17D-E3B4-4C40-8889-7C410E130BAD</gtr:id><gtr:title>Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb0cc0109e179d19fdeb7c8dc774a9c6"><gtr:id>bb0cc0109e179d19fdeb7c8dc774a9c6</gtr:id><gtr:otherNames>Hirschfield GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>58c147d9edadb7.42485490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD272F14-34FA-421E-AD15-2196057F2B5F</gtr:id><gtr:title>Editorial: fenofibrate as second-line therapy in high risk PBC--more answers or more questions?</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0624396d5239dd81c84ef38c5d6c9399"><gtr:id>0624396d5239dd81c84ef38c5d6c9399</gtr:id><gtr:otherNames>Jones DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>58c149c9a07573.55587359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61337DBB-1FBC-4BAB-BB33-0E8800ECB62E</gtr:id><gtr:title>Diagnosis and management of patients with primary biliary cirrhosis</gtr:title><gtr:parentPublicationTitle>Clinical Liver Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beaf6c0ec02c1382e9c09374437d33e6"><gtr:id>beaf6c0ec02c1382e9c09374437d33e6</gtr:id><gtr:otherNames>Dyson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461f2f30291c4.58973490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E39F69FE-C7E5-4339-9183-E2167D48A26E</gtr:id><gtr:title>Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0c70a64fb92e56b970dff99f17964ae"><gtr:id>f0c70a64fb92e56b970dff99f17964ae</gtr:id><gtr:otherNames>Sarafian MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>585d578fdbb951.91898727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>054C431E-8BB7-49B8-9D61-DDD80C0E56F5</gtr:id><gtr:title>The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d4b10bef9940042a07f07fab866601"><gtr:id>11d4b10bef9940042a07f07fab866601</gtr:id><gtr:otherNames>Carbone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56cc7d06646f43.37350284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4285A538-5170-4588-AF06-E5AB967F63A7</gtr:id><gtr:title>Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>The lancet. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ed6f4f497449fe1878010c3b6afd47e"><gtr:id>4ed6f4f497449fe1878010c3b6afd47e</gtr:id><gtr:otherNames>Jones D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a9e72b19948f8.31723525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0D4354E-29F2-47D6-B94F-D47CFEDB3969</gtr:id><gtr:title>The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df2edbaa1215d66fb561f6798d413656"><gtr:id>df2edbaa1215d66fb561f6798d413656</gtr:id><gtr:otherNames>Dyson JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>585d38f74dfc29.42143689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>308C21D2-F36C-4F40-BC85-392B9658E493</gtr:id><gtr:title>Health related quality of life in people with advanced chronic liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e616040fa72f24472deec98001b5e4f"><gtr:id>6e616040fa72f24472deec98001b5e4f</gtr:id><gtr:otherNames>Orr JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5461f2bd380bb0.00843606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F76199-7D78-44CF-B9F4-D8B1942B82E2</gtr:id><gtr:title>International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30f2ddcf341db5f03b7129b8dc29e57a"><gtr:id>30f2ddcf341db5f03b7129b8dc29e57a</gtr:id><gtr:otherNames>Cordell HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56cc7d05c30b69.42934997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBFCF3F2-50EC-43BB-9E99-7CD2A5C6738A</gtr:id><gtr:title>Novel therapeutic targets in primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df2edbaa1215d66fb561f6798d413656"><gtr:id>df2edbaa1215d66fb561f6798d413656</gtr:id><gtr:otherNames>Dyson JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>5461f377c58953.41294449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E1D028A-7930-42DC-8196-B0418185D56E</gtr:id><gtr:title>RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8b3a98515dda0ce4f419ee1dee150db"><gtr:id>a8b3a98515dda0ce4f419ee1dee150db</gtr:id><gtr:otherNames>Jopson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>56d83b3229fbb2.84532950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD2D8CAF-395E-4090-803A-D6087028A9DD</gtr:id><gtr:title>Risk stratification in primary biliary cirrhosis using the UK-PBC Research Cohort</gtr:title><gtr:parentPublicationTitle>Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d4b10bef9940042a07f07fab866601"><gtr:id>11d4b10bef9940042a07f07fab866601</gtr:id><gtr:otherNames>Carbone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461e10b24d517.93836369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22CF3E91-272D-45A7-912F-CA37C0780443</gtr:id><gtr:title>Patient experience and characteristics of cholestatic pruritus in the UK-PBC Research Cohort</gtr:title><gtr:parentPublicationTitle>Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00bf7e61704af89a644d08942a3a5ecb"><gtr:id>00bf7e61704af89a644d08942a3a5ecb</gtr:id><gtr:otherNames>Hegade VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461e21e96de84.98411437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84440F76-A302-40D0-906B-E2526DD61BF2</gtr:id><gtr:title>Exercise therapy in primary biliary cirrhosis: the importance of moving while sitting on a surgical waiting list-a case study.</gtr:title><gtr:parentPublicationTitle>Frontline gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/905af152408bdc17a8ec331511f59737"><gtr:id>905af152408bdc17a8ec331511f59737</gtr:id><gtr:otherNames>Hallsworth K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-4137</gtr:issn><gtr:outcomeId>58c14a9e9c1679.06253705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CD6A0DD-0256-4383-8F00-88C64CC44927</gtr:id><gtr:title>Stratified medicine and Primary Biliary Cholangitis: A good start but a lot still to do</gtr:title><gtr:parentPublicationTitle>Lancet Gastroenterol Hepatol</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58c81227997232.86710363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2073061-247C-4BD9-9DF3-4331A1B4BA39</gtr:id><gtr:title>Biliary epithelial senescence and plasticity in acute cellular rejection.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d667177fd9ab40e178dcb3bc949afe3f"><gtr:id>d667177fd9ab40e178dcb3bc949afe3f</gtr:id><gtr:otherNames>Brain JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>5461fe5fdbbdd1.62462206</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L001489/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>